Does the medical procedure of insulin potentiation as a treatment adhere to the concept of evidence-based medicine, are there articles in the medical literature that support the procedure?
Well, the answer to these two questions is yes. If it adheres to what has been called evidence-based medicine, since it does not use new drugs, it only proposes a modified use with the pharmacological effects of insulin to administer drugs and if there are multiple articles that talk about non-diabetic uses of insulin , the use of insulin as a potentiator of chemical substances and other articles that describe how the potentiated insulin protocol works. Although it has been several years since the phenomenon of cell membrane permeabilization was observed and understood by Dr. Donato Pérez García (1896-1971) who, starting in 1930, realized that medicine applied to his patients using a insulin dose and thus achieved cures and/or improvements in less time, with better results and with minimal side effects.
This concept of evidence-based medicine was adopted at the end of the 1990s. The Group of Canadian Physicians who proposed it did so with the intention of organizing knowledge and the results of controlled studies in order to make decisions that offered the best treatment with the best outcome for the patient. But this cannot necessarily be applied to all cases, much less when the vast majority of current medicine focuses on treating the symptom or symptoms and not the cause.
We already have better techniques to make diagnoses, that is, based on the symptoms that a patient has and the findings that are reported in laboratory and imaging (radiological) tests, we can establish a more accurate diagnosis and therefore we can decide what treatment will give the best result. Technology is helping to improve equipment, design new devices and recently to create diagnostic equipment that can give results to diagnose the changes that precede the development of a disease. However, if we only continue to attend to the symptoms, we are leaving the cause in the body unresolved. If the patient has a tumor, the treatment, which can be surgery, or radiation, or the new cryoablation procedures (inserting a needle into the tumor to freeze it or inject it with medicine), is still only symptom treatment. In some cases, treating only the symptom helps, but it will not always be the solution.
We know that the disease develops within the cell due to one or several alterations of its components and these alterations are reflected as physicochemical changes. What I need to do as a doctor: To be able to open the cell membrane in a controlled way to inject the drugs that enter the cell interior and these reverse the physicochemical alterations and thus restore the state of health. This process of opening the cell membrane happens in our body due to the action of the hormone insulin and happens from the time the fetus begins to have heartbeats or before. Without insulin the baby does not develop. So the doctor Donato Pérez Garcia, who in the year 1930 observed the effect of the permeability of the cell membrane, understood it and applied it, achieved better results with his treatment in patients. Insulin does not cure, insulin was discovered by Canadian doctors, Banting, Best, McLeod and Collip. The Mexican doctor Donato Pérez García (1896-1970) understood that the disease occurred within the cell and therefore physicochemical changes would have to be made to achieve a cure. He did conduct studies and published in medical journals beginning in 1937.
Dr. Donato had the vision and ability to understand the phenomenon of permeabilization caused by insulin and based on his observations made in his patients (“I apply it and it improves”) he acquired experience in the use of insulin. This is how the changes begin, someone does something new, is criticized because there is no history, but what he does gives results, you continue doing your treatment that works for many patients. So this medical procedure has medical articles in medical journals that expose the good results obtained. Finally, in this procedure no medicines are invented, known chemical substances (medicines) approved by the Health authority are used. What does the doctor who uses this administration therapy do: adapt the dose to be administered to the patient, taking into account that insulin potentiates the action of the drug at the intracellular level and therefore the dose is lower. Below is the list of medical references on non-diabetic uses of insulin in chronic-degenerative diseases and cancer.
Publications and Essays on IPT, also Supportive Studies – Published clinical and in-vitro studies that support the use of insulin as a biologic response modifier.
1)Poster Presentation at the Third Annual Comprehensive Cancer Management Conference, Washington, DC June 2000
Primary Breast Conserving Treatment for Breast Cancer Using Biologic Response Modification with Insulin in Combination with Non-Toxic Low-Dose Chemotherapy. Steven G. Ayre, M.D.
2)Insulin Shows Promise
Oncology News, 1991, 17(4):1,7
3) Ayre SG, Perez Garcia y Bellon D, Perez Garcia Jr D. Neoadjuvant low-dose chemotherapy with insulin in breast carcinomas. Eur J Cancer. 26:1261-2, 1990
4) Ayre SG, Perez Garcia Y Bellon D, Perez Garcia Jr D. Insulin potentiation therapy: a new concept in the management of chronic degenerative disease. Medical Hypotheses 20:199-210, 1986
5) Lippman ME, Dickson RB, Kasid A, et al. Autocrine and paracrine growth regulation of human breast cancer. J Steroid Biochem 24:147-154, 1986
6) Hilf R. The actions of insulin as a hormonal factor in breast cancer. In: Pike MC, Siiteri PK, Welsch CW, eds. Hormones and Breast Cancer, Cold Spring Harbor Laboratory, 1981, 317-337.
7) Cullen JK, Yee D, Sly WS, et al. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 50:48-53, 1990
8) Holdaway IM, Freisen HG. Hormone binding by human mammary carcinoma. Cancer Res 37:1946-1952, 1977
9) Papa V, Pezzino V, Constantino A, et al. Elevated insulin receptor content in human breast cancer. J Clin Invest 86:1503-1510, 1990
10) Sporn MB, Todaro GJ. Autocrine secretion and malignant transformation of cells. N Engl J Med 308:487-490, 1980
11) Jaques G, Rotsch M, Wegmann C, et al. Production of immunoreactive insulin-like growth factor 1 and response to exogenous IGF-1 in small cell lung cancer cell lines. Exp Cell Res 176:336-343, 1988
12) Nakanishi Y, Mulshine JL, Kasprzyk PG, et al. Insulin-like growth factor-1 can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest 82:354-359, 1988
13) Lee PDK, Rosenfeld RG, Hintz RL, Smith SD. Characterization of insulin, insulin-like growth factors I and II, and growth hormone receptors on human leukemic lymphoblasts. J Clin Endocr Metab 62:28-35, 1986
14) Colman PG, Harrison LC. Structure of insulin/insulin-like growth factor-1 receptors on the insulinoma cell, RIN-m5F. Biochem Biophys Res Commun 124:657-662, 1984
15) Zapf J, Froesch ER. Insulin-like growth factors/somatomedins: structure, secretion, biological actions and physiological role. Hormone Res 24:121-130, 1986
16) Papa V, Constance CR, Brunetti A, et al. Progestins increase insulin receptor content and insulin stimulation of growth in human breast carcinomas. Cancer Res 50:7857-7862, 1990
17) Stewart AJ, Johnson MD, May REB, Westley RB. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 265:21172-21178, 1990
18) Eppenberger U. New aspects in the molecular growth regulation of mammary tumors. In: Eppenberger U, Goldhirsch A, eds. Recent Results in Cancer Research, Vol. 113: Endocrine Therapy and Growth Regulation of Breast Cancer. Berlin-Heidelberg, 1989, 1-3
19) DeLeon DD, Bakker B, WIlson RL, et al. Demonstration of insulin-like growth factor (IGF-I and IGF-II) receptors and binding protein in human breast cancer cell lines. Biochem Biophys Res Commun 152:398-405, 1988
20) Karey KP, Sirbasku DA. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17B-estradiol. Cancer Res 48:4083-4092, 1988
21) King GL, Kahn CR, Rechler MM, Nissley SP. Direct demonstration for separate receptors for growth and metabolic activities of insulin and multiplication-stimulating activity (an insulin-like growth factor) using antibodies to the insulin receptor. J Clin Invest 66:130-140, 1980
22) Jacobs S, Cook S, Svoboda M, Van Wyk JJ. Interaction of the monoclonal antibodies alpha-IR-1 and alpha-IR3 with insulin and somatomedin-C receptors. Endocrinol 118:223-226, 1986
23) Goustin AS, Leof EB, Shipley GD, Moses HL. Growth factors and cancer. Cancer Res 46:1015-1029, 1986
24) Unterburger P, Sinop A, Noder w, et al. Diabetes mellitus and breast cancer: a retrospective follow-up study. Onkologie 13:17-20, 1990
25) Yee D, Palk S, Lebovic GS, et al. Analysis of insulin-like growth-factor I gene expression: evidence for a paracrine role in human breast cancer. Mol Endocrinol 3:509-517, 1990
26) Hilf R. Primary and permissive actions of insulin in breast cancer. In: Leung BS, ed. Hormonal regulation of mammary tumors. Montreal, Eden Press, 1982, Vol. 2, 123-137
27) Alabaster O, Vonderhaar BK, Shafie SM. Metabolic modification by insulin enhances methotrexate cytotoxicity in MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol 17:1223-1228, 1981
28) Oster JB, Creasey WA. Enhancement of cellular uptake of ellipticine by insulin preincubation. Eur J Cancer Clin Oncol 17:1097-1103, 1981
29) Schilsky RL, Bailey BD, Chabner BA. Characteristics of membrane transport of methotrexate by cultured human breast cancer cells. Biochem Pharmacol 30:1537-1542, 1981
30) Shinitzky M, Henkart P. Fluidity of cell membranes – current concepts and trends. Int Rev Cytol 60:121-147, 1971
31) Jeffcoat R. The biosynthesis of unsaturated fatty acids and its control in mammalian liver. Essays Biochem 15:1-36, 1979
32) Gasparro FP, Knobler RM, Yemul SS, Bisaccia E, Edelson RL. Receptor mediated photo-cytotoxicity: synthesis of a photoactivatable psoralen derivative conjugated to insulin. Biochem Biophys Res Comm 141:502-209, 1986
33) Poznansky MJ, Singh R, Singh B. Insulin: carrier potential for enzyme and drug therapy. Science 223:1304-1306, 1984
34) Ayre SG. New approaches to the delivery of drugs to the brain. Med Hypotheses 29:283-291, 1989
35) Gross GE, Boldt DH, Osborne CK. Perturbation by insulin of human breast cancer cell kinetics. Cancer Res 44:3570-3575, 1984
36) Paridaens R, Klijn JGM, Julien JP, et al. Chemotherapy with estrogenic recruitment in breast cancer: experimental background and clinical studies conducted by the EORTC breast cancer cooperative group. Eur J Cancer Clin Oncol 22:728, 1986
37) Van der Burg B, de Laat SW, van Zoelen EJJ. Mitogenic stimulation of human breast cancer cells in a growth-factor defined medium: synergistic action of insulin and estrogens. In: Brescani F, King RGB, Lippman ME, Raynaud JP, eds. Progress in Cancer Research and Therapy, vol. 35: Hormones and Cancer 3. New York, Raven Press, Ltd. 1988, 231-233.
38) Goldfine ID, Purello F, Vigneri R, and Clawson GA. Direct regulation of nuclear functions by insulin: relationship to mRNA metabolism. In: Czech MP, ed. Molecular Basic of Insulin Action. New York, Plenum Press, 1985, 329-345.
39)Blood Brain Barrier Passage of Azidothyumidine in Rats: Effects of Insulin
Steven G. Ayre (1), Brian Skaletski (2) and Aron D. Mosnaim( 2).
Research Communications in Chemical Pathology and Pharmacology JANUARY 1989 VOL.63, NO. 1. Departments of Family Medicine and Pharmacology and Molecular Biology , University of Health Sciences/The Chicago Medical School, North Chicago, IL 60064.
40)New Approaches to Delivery of Drugs to the Brain. S.G. Ayre. Medical Hypotheses 29:283-291, 1989
41)Insulin, chemotherapy, and the mechanisms of malignancy: the design and the demise of cancer. S.G. Ayre, M.D., D. P. Garcia Bellon, M.D., D. P. Garcia, Jr., M.D. Medical hypotheses 55.4 (2000): 330-334.
42)Low dose chemotherapy in combination with insulin for the treatment of metastatic tumors: C. Damyanov, M. Radoslavova, V. Gavrilov, D. Stoeva. Medical Center of Integrative Medicine, Sofia, Bulgaria. Journal of BUON 14: 711-15, 2009.
43)Insulin Potentiation Therapy in the treatment of malignant neoplastic diseases: a three year study. Damyanov C, Gherasimova DM, Avramov LA, Masley IK (2012). J Cancer Sci Ther 4: 088-091. doi:10.4172/1948-5956.1000117
44)Low-Dose Chemotherapy with insulin (Insulin Potentiation Therapy) in combination with hormone therapy for treatment of castration-resistant prostate cancer. Damyanov, Christo, et al. ISRN urology 2012 (2012).
45)Metabolic Modification by Insulin Enhances Methotrexate Cytotoxicity in MCF-7 Human Breast Cells. Alabaster, O. Vonderhaar, B. and Shafie, S. Eur J Cancer Clin Oncol. Vol 17, No. 11, pp 1223-1228. 1961.
46)Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Lundholm K, Körner U, Gunnebo L, Sixt-Ammilon P, Fouladiun M, Daneryd P, Bosaeus I. Clin Cancer Res. 2007 May 1;13(9):2699 706.
47)Long-Term Effect of Diabetes and Its Treatment on Cognitive Function. Jacobson, Alan, et.al. N Engl J Med 2007; 356:1842-52.
48)Preclinical safety and antitumor efficacy of insulin combined with irradiation. Bénédicte F. Jordan, Nelson Beghein, Nathalie Crokart, Christine Baudelet, Vincent Gregoire, Bernard Gallez. Radiotherapy and Oncology 81 (2006) 112–117.
49)Insulin-induced enhancement of antitumoral response to methotrexate in breast cancer patients. Lasalvio-Prisco, Eduardo, et.al. Cancer Chemother Pharmacol (2004) 53: 220–224.
50)The effect of insulin on chemotherapeutic drug sensitivity in human esophageal and lung cancer cells. Zhonghua Yi Xue Za Zhi. 2003 Feb 10;83(3):195-7.
51)Pretreatment with insulin enhances anticancer functions of 5-fluorouracil in human esophageal and colonic cancer cells. Zou K, Ju JH, Xie H. Acta Pharmacol Sin. 2007 May; 28(5):721-30.
52)A pilot study of Auron Misheil Therapy (AMT) in patients with advanced cervical cancer: tumor response and its correlation with clinical benefit response, and preliminary quality of life data.” Scheele, Jürgen, et al. Oncology reports 22.4 (2009): 877-883.
53)Insulin in endometrial carcinoma chemotherapy: A beneficial addition and not a problem. Sha, Huilan, et al. Journal of Huazhong University of Science and Technology [Medical Sciences] 30 (2010): 631-637.
54) Insulin for Everything. TIME magazine April 10, 1944
55)Long-Term Outcomes of the Treatment of Unresectable (Stage III - IV)Ductal Pancreatic Adenocarcinoma Using Metabolically Supported Chemotherapy (MSCT): A Retrospective Study
Mehmet Salih Iyikesici1, Ayshe Slocum2*, Engin Turkmen3, Ovunc Akdemir4, Abdul Kadir Slocum5, Turgut Ipek6, Erhun Eyuboglu6, Ferhan Bulent Berkarda7
56)Efficacy of Metabolically Supported Chemotherapy Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy for Stage IV Triple-Negative Breast Cancer. Mehmet Salih İyikesici, Abdul Kadir Slocum, Ayshe Slocum, Ferhan Bulent Berkarda, Miriam Kalamian, andThomas N Seyfried. Cureus. 2017 Jul; 9(7): e1445.Published online 2017 Jul 7. doi: 10.7759/cureus.1445. PMCID: PMC5589510. Monitoring Editor: Alexander Muacevic and John R Adler
57)Integrative Oncology at the Clinicist's Look. Chronology for the Creation and Development of the IPT & BMP Method for Treatment of Oncological Diseases. It is uploaded on the following link: http://www.clinicsinoncology.com/pdfs_folder/cio-v4-id1671.pdf .
#ipt #iptld #iptldacademy #LegacyIPT #integrativemedicine #integrativecancer #naturalmedicine #alternativecancercare #cancersurvivor #cancer #cancersucks #cancerawareness #breastcancer #cancerfighter #cancerwarrior #cancersupport #cancerfree #chemotherapy #survivor #health #breastcancersurvivor #cancerdemama #cancerresearch #chemo #cancertreatment #cancercare #oncology #beatcancer #cancersurvivors #lifeaftercancer #repost #fightcancer